Modality
Peptide
MOA
PD-L1i
Target
Cl18.2
Pathway
Innate Imm
SLEPsAPsoriasis
Development Pipeline
Preclinical
~Mar 2024
→ ~Jun 2025
Phase 1
Sep 2025
→ Jun 2030
Phase 1Current
NCT05424165
1,281 pts·PsA
2025-09→2030-06·Completed
1,281 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-194.2y awayInterim· PsA
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1
Complet…
Catalysts
Interim
2030-06-19 · 4.2y away
PsA
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05424165 | Phase 1 | PsA | Completed | 1281 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 |